News
🌏 Asia-PacificLatest pharmaceutical news, drug approvals, and NMPA regulatory updates
Latest News
Telemedicine in APAC: Opportunities & Challenges for Pharma Firms
Telemedicine offers APAC pharma firms unique opportunities and challenges, reshaping patient access to medications like Lipitor for effective cholesterol control.
NMPA Grants Breakthrough Therapy Designation to Innovent's KRAS G12C Inhibitor
The NMPA has granted breakthrough therapy designation to Innovent's KRAS G12C inhibitor, marking a significant advancement in the treatment of advanced solid tumors.
PMDA Accepts Shionogi Novel Influenza Drug with SAKIGAKE Designation
The PMDA has accepted Shionogi's novel influenza drug, recognized with SAKIGAKE designation, marking a significant advancement in flu treatment.
Growth of Generics Market India: Impact of CDSCO Policy Changes on Pricing
This article examines the rapid growth of the generics market in India, highlighting the impact of CDSCO policy changes on drug pricing and accessibility.
PMDA SAKIGAKE Designation: Accelerating Regenerative Medicine Market Access in Japan
Explore the impact of PMDA SAKIGAKE Designation on speeding up access to regenerative medicine in Japan, enhancing treatment options for patients.
NMPA Priority Review Pathway: Accelerating Oncology & Rare Disease Drug Approvals
The NMPA Priority Review Pathway significantly speeds up the approval process for oncology and rare disease drugs, ensuring timely access to life-saving therapies.
PMDA Expedited Review Melanoma: Impact on Japanese Treatment Paradigms
The PMDA's expedited review process for melanoma therapies, including Keytruda, is transforming treatment paradigms in Japan, enhancing patient access to innovative care.
Australian Biotech Solid Tumor CAR-T: What You Need to Know
Explore the advancements in Australian Biotech's CAR-T therapy for solid tumors, offering new hope for patients battling cancer.
NMPA GMP Standards: Key Updates and Impact on Foreign Pharma Manufacturers
This article explores key updates to NMPA GMP standards and their significant implications for foreign pharmaceutical manufacturers in the Chinese market.
NMPA Accelerated Approval Orphan Drugs: Impact & Future Trends in China
This article delves into the NMPA's accelerated approval process for orphan drugs, focusing on its implications for rare disease treatments in China.
ICH Guidelines Biosimilar Development: Impact on APAC Approval Timelines
This article delves into ICH guidelines for biosimilar development, highlighting their influence on approval timelines in the APAC region for critical therapies.
Biosimilar Market Growth India: Key Drivers, Challenges & Opportunities
The biosimilar market in India is poised for significant growth, driven by increasing demand for affordable biologics like Trastuzumab, alongside various challenges and opportunities.
Adalimumab Biosimilars Uptake: Australia vs Japan Market Analysis
This article analyzes the market dynamics of Adalimumab biosimilars in Australia and Japan, highlighting differences in uptake and patient access for rheumatoid arthritis.
PMDA Biosimilar Framework: Impact on Trastuzumab Biosimilars in Japan
This article delves into the PMDA biosimilar framework and its significant influence on the development and approval of trastuzumab biosimilars in Japan.
NMPA Biosimilar Approval Pathway: What You Need to Know
Explore the NMPA biosimilar approval pathway for adalimumab, focusing on essential steps and requirements for gaining market access in China.
Pompe Disease Treatments APAC: Market Growth and Regulatory Insights
This article delves into the evolving landscape of Pompe Disease treatments in the APAC region, highlighting market growth and key regulatory developments.
Bevacizumab Biosimilar Approval China: NMPA Greenlights First Biosimilar
The NMPA has approved the first biosimilar of Bevacizumab, a groundbreaking step for cancer treatment accessibility in China.
Australia Leads APAC Early Phase Trials: TGA Pathways Analysis 2024
Australia is at the forefront of APAC early phase trials, analyzing TGA pathways for drugs like Ozempic, enhancing diabetes treatment options in 2024.